Researchers found that individuals with unexplained neurodevelopmental disorders and congenital anomalies had an enrichment of de novo epivariations.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.
The Epigenetics For Female Personalised Cancer Care (EpiFemCare) project recently published its findings in two papers in the journal Genome Medicine.
The partners will perform blood-based tests on Oxford's Episwitch platform to monitor epigenetic changes of athletes with concussions.
The Salk Institute-led team developed a system for in vivo activation of endogenous target genes through trans-epigenetic remodeling.
In Nature this week: new class of base editors, additional breast cancer risk loci, and more.
In Nucleic Acids Research this week: disease network resource, database of epigenetic consequences of de novo mutations, and more.
Such an atlas could enable investigators to understand how genetic variants impact disease risk, define drug toxicities, improve therapies, and advance regenerative medicine.
Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.
Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.
Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.
In Science this week: gut microbiome influences liver cancer growth, spread; and more.